Cargando…

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes

Breast cancer is a complex disease encompassing multiple tumor entities, each characterized by distinct morphology, behavior and clinical implications. Besides estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, novel biomarkers have shown their prognostic and pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xiaofeng, Xiang, Liangjian, Li, Ting, Bai, Zhonghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934037/
https://www.ncbi.nlm.nih.gov/pubmed/27390604
http://dx.doi.org/10.7150/jca.13141
_version_ 1782441272097636352
author Dai, Xiaofeng
Xiang, Liangjian
Li, Ting
Bai, Zhonghu
author_facet Dai, Xiaofeng
Xiang, Liangjian
Li, Ting
Bai, Zhonghu
author_sort Dai, Xiaofeng
collection PubMed
description Breast cancer is a complex disease encompassing multiple tumor entities, each characterized by distinct morphology, behavior and clinical implications. Besides estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, novel biomarkers have shown their prognostic and predictive values, complicating our understanding towards to the heterogeneity of such cancers. Ten cancer hallmarks have been proposed by Weinberg to characterize cancer and its carcinogenesis. By reviewing biomarkers and breast cancer molecular subtypes, we propose that the divergent outcome observed from patients stratified by hormone status are driven by different cancer hallmarks. 'Sustaining proliferative signaling' further differentiates cancers with positive hormone receptors. 'Activating invasion and metastasis' and 'evading immune destruction' drive the differentiation of triple negative breast cancers. 'Resisting cell death', 'genome instability and mutation' and 'deregulating cellular energetics' refine breast cancer classification with their predictive values. 'Evading growth suppressors', 'enabling replicative immortality', 'inducing angiogenesis' and 'tumor-promoting inflammation' have not been involved in breast cancer classification which need more focus in the future biomarker-related research. This review novels in its global view on breast cancer heterogeneity, which clarifies many confusions in this field and contributes to precision medicine.
format Online
Article
Text
id pubmed-4934037
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-49340372016-07-07 Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes Dai, Xiaofeng Xiang, Liangjian Li, Ting Bai, Zhonghu J Cancer Review Breast cancer is a complex disease encompassing multiple tumor entities, each characterized by distinct morphology, behavior and clinical implications. Besides estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, novel biomarkers have shown their prognostic and predictive values, complicating our understanding towards to the heterogeneity of such cancers. Ten cancer hallmarks have been proposed by Weinberg to characterize cancer and its carcinogenesis. By reviewing biomarkers and breast cancer molecular subtypes, we propose that the divergent outcome observed from patients stratified by hormone status are driven by different cancer hallmarks. 'Sustaining proliferative signaling' further differentiates cancers with positive hormone receptors. 'Activating invasion and metastasis' and 'evading immune destruction' drive the differentiation of triple negative breast cancers. 'Resisting cell death', 'genome instability and mutation' and 'deregulating cellular energetics' refine breast cancer classification with their predictive values. 'Evading growth suppressors', 'enabling replicative immortality', 'inducing angiogenesis' and 'tumor-promoting inflammation' have not been involved in breast cancer classification which need more focus in the future biomarker-related research. This review novels in its global view on breast cancer heterogeneity, which clarifies many confusions in this field and contributes to precision medicine. Ivyspring International Publisher 2016-06-23 /pmc/articles/PMC4934037/ /pubmed/27390604 http://dx.doi.org/10.7150/jca.13141 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Review
Dai, Xiaofeng
Xiang, Liangjian
Li, Ting
Bai, Zhonghu
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title_full Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title_fullStr Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title_full_unstemmed Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title_short Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
title_sort cancer hallmarks, biomarkers and breast cancer molecular subtypes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934037/
https://www.ncbi.nlm.nih.gov/pubmed/27390604
http://dx.doi.org/10.7150/jca.13141
work_keys_str_mv AT daixiaofeng cancerhallmarksbiomarkersandbreastcancermolecularsubtypes
AT xiangliangjian cancerhallmarksbiomarkersandbreastcancermolecularsubtypes
AT liting cancerhallmarksbiomarkersandbreastcancermolecularsubtypes
AT baizhonghu cancerhallmarksbiomarkersandbreastcancermolecularsubtypes